I'm not concerned about the impact on the consumer. However, if Star felt it was a good business strategy to take it off the shelves -- or let it be taken off the shelves without so much as a fight -- it would be a dick move for current users. It would be irresponsible, particularly if they are convinced this compound is superior to anything else out there.
No, my concern is from the standpoint of an investor: How will they proceed given the conflicting regulatory paths? What are the consequences to the 'supplement', as they position and advance it as a viable 'drug'?
And, because of the near-term uncertainties, they need to have clear and competent back-up plans -- whichever way the pendulum swings -- and articulate them (to shareholders) promptly and accordingly, as these issues come to pass.
